1. Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: A multicenter retrospective analysis. (February 2017) Authors: De Lisi, D.; Maruzzo, M.; Galli, L.; Biasco, E.; Farnesi, A.; Procopio, G.; Ratta, R.; Buti, S.; Sternberg, C.N.; Cerbone, L.; Di Lorenzo, G.; Pantano, F.; Sterpi, M.; De Giorgi, U.; Berardi, R.; Torinai, M.; Camerini, A.; Massari, F.; Tonini, G.; Santini, D. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S190 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 889PBroad immunomodulating effect of first-line pazopanib in metastatic renal cell carcinoma patients. (18th September 2017) Authors: Verzoni, E.; De Cecco, L.; Dugo, M.; Rinchai, D.; Bedognetti, D.; Grassi, P.; Ratta, R.; Cova, A.; Squarcina, P.; Huber, V.; Montone, R.; Sorrentino, M.; Procopio, G.; Rivoltini, L. Journal: Annals of oncology Issue: Volume 28(2017)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis. (November 2021) Authors: Ciccarese, C.; Iacovelli, R.; Porta, C.; Procopio, G.; Bria, E.; Astore, S.; Cannella, M.A.; Tortora, G. Journal: Cancer treatment reviews Issue: Volume 100(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 3LBA CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC). (September 2015) Authors: Sharma, P.; Escudier, B.; McDermott, D.F.; George, S.; Hammers, H.J.; Srinivas, S.; Tykodi, S.S.; Sosman, J.A.; Procopio, G.; Plimack, E.R.; Castellano, D.; Gurney, H.; Donskov, F.; Bono, P.; Wagstaff, J.; Gauler, T.C.; Ueda, T.; Xu, L.A.; Waxman, I.M.; Motzer, R.J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S708 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial. Issue 2 (1st February 2021) Authors: Mennitto, A.; Verzoni, E.; Cognetti, F.; Miceli, R.; Milella, M.; Mosca, A.; Chiuri, V. E.; Bearz, A.; Morelli, F.; Ortega, C.; Atzori, F.; Donini, M.; Claps, M.; Guadalupi, V.; Sepe, P.; Cappelletti, V.; de Braud, F. G.; Procopio, G. Journal: Expert review of clinical pharmacology Issue: Volume 14:Issue 2(2021) Page Start: 261 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 2549 Treatment patterns in patients (pts) with metastatic castrationresistant prostate cancer (mCRPC) previously treated with docetaxel (DOC)-based chemotherapy (CT): PROXIMA 1-year analysis. (September 2015) Authors: Akaza, H.; Procopio, G.; Pripatnanont, C.; Facchini, G.; Fava, S.; Wheatley, D.; Leung, K.C.; Butt, M.; Silva, A.; Castillo, L.; Karavasilis, V.; Hitier, S.; Ecstein-Fraisse, E.B.; Bensfia, S.; roglu, M. Ö zgü Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S492 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 2603 Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs). (September 2015) Authors: Santini, D.; Santoni, M.; Conti, A.; Procopio, G.; Verzoni, E.; Galli, L.; Di Lorenzo, G.; De Giorgi, U.; De Lisi, D.; Nicodemo, M.; Maruzzo, M.; Massari, F.; Buti, S.; Biasco, E.; Ricotta, R.; Porta, C.; Vincenzi, B.; Marchetti, P.; Cascinu, S.; Tonini, G. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S512 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗